InVivoSIM anti-human IFNγ (Emapalumab Biosimilar)

About InVivoSIM anti-human IFNγ (Emapalumab Biosimilar)

This non‑therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Emapalumab making it ideal for research use. Emapalumab is a fully human IgG1 monoclonal antibody that specifically binds interferon‑gamma (IFNγ), both free and receptor-bound forms, to prevent its interaction with the IFNγ receptor. IFNγ is a 20 kDa soluble pleiotropic cytokine and the sole member of the type II class of interferons. IFNγ is primarily produced by activated lymphocytes including T, B, NK cells, and ILCs. IFNγ exerts immunoregulatory, anti-proliferative, anti-viral, and proinflammatory activities and plays an important role in activation, growth, and differentiation of T and B lymphocytes, macrophages, NK cells and other non-hematopoietic cell types. Additionally, IFNγ induces the production of cytokines, Fc receptor, and adhesion molecules and up-regulates MHC class I and II antigen expression by antigen presenting cells during an immune response. IFNγ has also been shown to modulate macrophage effector functions, influence isotype switching and induce the secretion of immunoglobulins by B cells. IFNγ signals through the IFN gamma receptor which exists as a heterodimer composed of CD119 (IFN gamma receptor 1) and AF-1 (IFN gamma receptor 2). The IFNγ receptor is expressed ubiquitously on almost all cell types with the exception of mature erythrocytes.